Abstracts tagged "Lupus and belimumab"

Abstract Number: 2650 • 2018 ACR/ARHP Annual Meeting
Efficacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus
Luca Iaccarino¹, Francesca Saccon¹, Alessandro Mathieu², Matteo Piga³, Angela Ceribelli⁴, Carlo Selmi⁵, Paolo Cardinaletti⁶, Armando Gabrielli⁷, Andrea Di Matteo⁸, Rossella De Angelis⁹, Paola Faggioli¹⁰, Antonella Laria¹¹, Micaela Fredi¹², Francesca Regola¹³, Angela Tincani¹², Laura Andreoli¹⁴, Giulia Pazzola¹⁵, Carlo Salvarani¹⁵, Francesco Puppo¹⁶, Ottavia Magnani¹⁶, Marcella Prete¹⁷, Elisa Gremese¹⁸, Maria Gerosa¹⁹, Tania Ubiali²⁰, Enrica Bozzolo²¹, Valentina Canti²¹, Vito Racanelli¹⁷, Fabrizio Conti²², Fulvia Ceccarelli²³, Elena Bartoloni²⁴, Roberto Gerli²⁵, Antonio Lobasso²⁶, Amato de Paulis²⁷, Ginevra De Marchi²⁸, Salvatore De Vita²⁹, Alessandra Bortoluzzi³⁰, Marcello Govoni³⁰, Francesco Benvenuti³¹, Margherita Zen³², Marta Mosca³³, Chiara Tani³⁴, Maurizio Rossini³⁵, Giovanni Orsolini³⁵, Salvatore Scarpato³⁶, Ernico Brunetta³⁷, Aurora Zumbo³⁸, Giacomo Tanti³⁹ and Andrea Doria⁴⁰, ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²University of Cagliari, Cagliari, Italy, ³Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ⁴Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ⁵Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ⁶University of Ancona, Ancona, Italy, ⁷Univeristy of Ancona, Ancona, Italy, ⁸Polytechnic University of Marche, Rheumatology Clinic, Jesi, Italy, ⁹Polytechnic University of Marche, Rheumatology Clinic, jesi, Italy, ¹⁰Hospital of Legnano, Legnano, Italy, ¹¹Hospital of Magenta, Magenta, Italy, ¹²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹³University of Brescia, Brescia, Italy, ¹⁴Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹⁵University of Reggio Emilia, Reggio Emilia, Italy, ¹⁶University of Genova, Genova, Italy, ¹⁷University of Bari, Bari, Italy, ¹⁸Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ¹⁹Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ²⁰Istituto Gaetano Pini, University of Milano, Milano, Italy, ²¹Hospital San Raffaele, Milano, Italy, ²²Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ²³UO Complessa Reumatologia, Policlinico Umberto I Università Sapienza di Roma, Rome, Italy, ²⁴Rheumatology Unit, University of Perugia, Perugia, Italy, ²⁵Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ²⁶University Federico II of Napoli, Napoli, Italy, ²⁷Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy, ²⁸Hospital/University of Udine, Udine, Italy, ²⁹Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ³⁰UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ³¹University of Padova, Padova, Italy, ³²Division of Rheumatology, University of Padova, Padova, Italy, ³³Rheumatology Unit, University of Pisa, Pisa, Italy, ³⁴Univeristy of Pisa, Pisa, Italy, ³⁵Rheumatology Unit, University of Verona, Verona, Italy, ³⁶Hospital of Salerno, Salerno, Italy, ³⁷Humanitas Hospital, Milano, Italy, ³⁸Humnaitas Hospital, Milano, Italy, ³⁹Catholic University of the sacred hearth, Roma, Italy, ⁴⁰University and Azienda Ospedaliera of Padova, Padova, Italy
Background/Purpose: To investigate effectiveness, safety, and predictors of response to belimumab in patients with active SLE in clinical practice setting. Methods: Four hundred and one…
Abstract Number: 780 • 2016 ACR/ARHP Annual Meeting
Belimumab Use in African-American Patients in an U.S. Academic Medical Center
Paloma Alejandro¹, Anjani Pillarisetty² and Christopher E. Collins³, ¹Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ²Internal Medicine, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ³MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC
Background/Purpose: Belimumab is an anti-BAFF monoclonal antibody approved for the treatment of auto-antibody positive patients with SLE. In two large phase 3 clinical trials, belimumab…